BRPI0414580A - derivado do ácido fenilacético, processos para sua produção e uso - Google Patents

derivado do ácido fenilacético, processos para sua produção e uso

Info

Publication number
BRPI0414580A
BRPI0414580A BRPI0414580-1A BRPI0414580A BRPI0414580A BR PI0414580 A BRPI0414580 A BR PI0414580A BR PI0414580 A BRPI0414580 A BR PI0414580A BR PI0414580 A BRPI0414580 A BR PI0414580A
Authority
BR
Brazil
Prior art keywords
alkyl
processes
production
acid derivative
phenylacetic acid
Prior art date
Application number
BRPI0414580-1A
Other languages
English (en)
Inventor
Shinya Kusuda
Yoshisuke Nakayama
Hisao Tajima
Takahiko Sakomoto
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Publication of BRPI0414580A publication Critical patent/BRPI0414580A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

"DERIVADO DO áCIDO FENILACéTICO, PROCESSOS PARA SUA PRODUçãO E USO". Descreve-se um composto representado pela fórmula geral (I): (I) (onde R¬ 1¬ e R¬ 2¬ representam cada qual, hidrogênio, C~ 1-8~ alquila, etc; R¬ 3¬ representa, ou C~ 1-8~ alquila opcionalmente substituído com 1-3 átomos de halogênio ou fenila; R¬ 4¬ representa hidrogênio etc.; R¬ 5¬ e R¬ 6¬ representam, cada qual, hidrogênio, C~ 1-8~ alquila, etc.; X representa enxofre, oxigênio, etc.; e o anel A representa um grupo cíclico opcionalmente substituído) ou um sal do mesmo. O composto representado pela fórmula geral (I) possui toxicidade extremamente baixa, sendo portanto, útil como um produto medicinal seguro. Ele possui atividade agonística para PPAR <sym>, sendo portanto, útil como um agente terapêutico preventivo e/ou terapêutico em doenças ocasionadas pelo metabolismo anormal de açúcar/lipídio, hipertensão, doenças circulatórias, etc.
BRPI0414580-1A 2003-09-22 2004-09-21 derivado do ácido fenilacético, processos para sua produção e uso BRPI0414580A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003330616 2003-09-22
JP2004231546 2004-08-06
PCT/JP2004/014137 WO2005028453A1 (ja) 2003-09-22 2004-09-21 フェニル酢酸誘導体、その製造方法および用途

Publications (1)

Publication Number Publication Date
BRPI0414580A true BRPI0414580A (pt) 2006-11-07

Family

ID=34380351

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414580-1A BRPI0414580A (pt) 2003-09-22 2004-09-21 derivado do ácido fenilacético, processos para sua produção e uso

Country Status (14)

Country Link
US (1) US7560475B2 (pt)
EP (1) EP1666472B1 (pt)
JP (1) JP4661595B2 (pt)
KR (1) KR20060121884A (pt)
AU (1) AU2004274337A1 (pt)
BR (1) BRPI0414580A (pt)
CA (1) CA2539554A1 (pt)
ES (1) ES2390053T3 (pt)
IL (1) IL174438A0 (pt)
MX (1) MXPA06003205A (pt)
NO (1) NO20061281L (pt)
NZ (1) NZ546031A (pt)
RU (1) RU2349587C2 (pt)
WO (1) WO2005028453A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2415983B (en) 2003-02-26 2007-09-05 Enventure Global Technology Apparatus for radially expanding and plastically deforming a tubular member
BRPI0615948A2 (pt) * 2005-09-07 2011-05-31 Plexxikon Inc composto ativo de ppar, sua composição, seu kit e seu uso
KR100806162B1 (ko) * 2006-11-30 2008-02-22 (주)아모레퍼시픽 식물유래 ＰＰＡＲｓ 활성물질을 함유하는 피부 외용제조성물
AU2007326395B2 (en) * 2006-12-01 2012-10-11 Msd K.K. Novel phenyl-isoxazol-3-ol derivative
FR2910893A1 (fr) * 2006-12-29 2008-07-04 Genfit Sa Derives de (phenylthiazolyl)-phenyl-propan-1-one et de (phenyloxazolyl)-phenyl-propan-1-one substitues, preparations et utilisations.
WO2011030104A1 (en) * 2009-09-09 2011-03-17 Rajiv Jalan Phenylacetate and/or phenylbutyrate (not ornithine) for reducing portal blood pressure
CN102285933B (zh) * 2010-06-18 2016-03-09 浙江海正药业股份有限公司 一种对亚型过氧化物酶增殖物激活受体具有激动作用的化合物、其制备方法和应用
RU2447082C1 (ru) * 2011-01-19 2012-04-10 Федеральное Государственное Бюджетное Учреждение "Научно-Исследовательский Институт Эпидемиологии И Микробиологии Имени Почетного Академика Н.Ф. Гамалеи" Министерства Здравоохранения И Социального Развития Российской Федерации Способ стимуляции регенерации дефектов кожи и слизистых оболочек и лекарственное средство для его реализации

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW222626B (pt) * 1991-07-22 1994-04-21 Pfizer
DE4427294C2 (de) 1994-08-02 1996-08-22 Kim Kyung Shin Dipl Designerin Verfahren zur Herstellung von Schmuck-, Dekorations- und Kunstgegenständen aus einer Metallfolie oder aus einem Metallnetz mit unregelmäßig gefalteter Struktur
JPH09168441A (ja) 1995-12-21 1997-06-30 Elecom Kk ラック
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
ATE451346T1 (de) 1998-03-10 2009-12-15 Ono Pharmaceutical Co Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten
GB9914977D0 (en) 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
US6417212B1 (en) * 1999-08-27 2002-07-09 Eli Lilly & Company Modulators of peroxisome proliferator activated receptors
JP4148681B2 (ja) * 2000-12-28 2008-09-10 武田薬品工業株式会社 アルカン酸誘導体、その製造法および用途
US20030092736A1 (en) * 2001-05-30 2003-05-15 Cheng Peter T. Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
US7259175B2 (en) * 2002-02-25 2007-08-21 Eli Lilly And Company Peroxisome proliferator activated receptor modulators
AU2003217274A1 (en) * 2002-02-25 2003-09-09 Eli Lilly And Company Peroxisome proliferator activated receptor modulators

Also Published As

Publication number Publication date
EP1666472B1 (en) 2012-08-01
JP4661595B2 (ja) 2011-03-30
IL174438A0 (en) 2006-08-01
JPWO2005028453A1 (ja) 2006-11-30
US7560475B2 (en) 2009-07-14
US20070105868A1 (en) 2007-05-10
MXPA06003205A (es) 2006-06-23
AU2004274337A1 (en) 2005-03-31
RU2006113612A (ru) 2007-10-27
NZ546031A (en) 2009-03-31
EP1666472A1 (en) 2006-06-07
RU2349587C2 (ru) 2009-03-20
EP1666472A4 (en) 2009-05-13
CA2539554A1 (en) 2005-03-31
WO2005028453A1 (ja) 2005-03-31
KR20060121884A (ko) 2006-11-29
NO20061281L (no) 2006-06-22
ES2390053T3 (es) 2012-11-06

Similar Documents

Publication Publication Date Title
CO5650227A2 (es) Derivados del acido propionico utiles en desordenes lipidicos
BG108318A (en) Carboxamide-substituted phenylurea derivatives and method for the production and use thereof as medicaments
BRPI0315296B8 (pt) derivados do ciclohexanol espirocíclicos, medicamento incluindo pelo menos um derivado do ciclohexano espirocíclico e uso de um derivado do ciclohexano espirocíclico
EA200000759A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
BRPI0409109A (pt) novos compostos
ES2061452T3 (es) Nuevas hetrazepinas y procedimiento para su preparacion.
SE0104334D0 (sv) Therapeutic agents
PT1213296E (pt) Derivados de glucopiranosiloxipirazole composicoes medicas que os contem e intermediarios na sua producao
DE60324180D1 (de) Behandlung der huntington&#39;s krankheit mit epa
EA200001223A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
EP1373207A4 (en) NEW AMLODIPINCAMSYLATE AND METHOD FOR THE PRODUCTION THEREOF
EA200200096A1 (ru) Новые производные витамина d с циклическими субструктурами в боковых цепях, способ и промежуточные продукты для их получения и их применение для получения лекарственных средств
BRPI0414580A (pt) derivado do ácido fenilacético, processos para sua produção e uso
AR029795A1 (es) Derivados de acido 1,2,3,4-tetrahidroquinolin-2-carboxilico sustituidos, procedimientos para su preparacion, su uso para la preparacion de medicamentos y medicamentos que contienen estos compuestos
ATE433450T1 (de) Substituierte 1,4,8-triazaspiro 4.5 decan-2-on- verbindungen
ATE424195T1 (de) Verwendung von 2-amino-1,3-propandiolderivaten zur herstellung eines medikaments zur behandlung von bestimmten schmerzen
SE0101978D0 (sv) New compounds
BRPI0411186A (pt) composição de sabão lìquido transparente e processo para a preparação da mesma
NO20063859L (no) Cykloalkylsubstituerte 7-amino-4-kinolon-3-karboksylsyrederivater, fremgangsmate for fremstilling derav og anvendelse derav som medikamenter
ATE503760T1 (de) Behandlung hochleistungsfähiger pigmentfarbstoffe mit dispergierenden etheramin-salzen
NO20053876D0 (no) Karbonylaminosubstituerte acylfenylurederivater, fremgangsmate for deres fremstilling samt anvendelse derav
UY28370A1 (es) Agentes terapéuticos
MY137679A (en) 2-ethoxy-3-phenylpropionic acid derivatives for the treatment of lipid disorders
AR041952A1 (es) N-sulfonilaminotiazol
MXPA04012685A (es) Derivados de acido benzoico orto-sustituidos para el tratamiento de la resistencia a la insulina.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.